Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
”Sometimes diagnosing drug-induced immune haemolytic anaemia (DIIHA) feels like chasing a unicorn among zebras.
What looks like a straightforward AIHA can suddenly turn on its head when a culprit drug is revealed.
A decade of pharmacovigilance data from France has now reminded us that the “usual suspects” (antibiotics, anti-inflammatories, etc.) are no longer alone—immune checkpoint inhibitors have officially joined the list.
The lesson is clear:
- Never underestimate the power of a careful drug history.
- A positive DAT is not the end of the story—it’s the start of the detective work.
- Always challenge your diagnostic assumptions before risking re-exposure.
As our therapeutic toolbox expands, so too does the responsibility to spot these rare but serious events.
Grateful for the international haematology community that keeps pushing vigilance forward and protecting patients.”
Read the full paper in BJ Haem.
Article: A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia
Authors: Guillaume Brenac, Anne Dautriche, Romane Freppel, Anthony Facile, Bruno Revol, Mathilde Beurrier, Bernard Bonnotte, Sylvain Audia
Stay informed on all the scientific advances in Hematology with Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 15:42The True Price of Gene Therapy: Breaking Down Beqvez’s $3.5M Cost and What Really Drives It
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 01:37Flora Peyvandi on Iron Deficiency in Mild to Moderate Bleeding Disorders
-
Sep 12, 2025, 07:28Lauren Murphy: Platelets as DNA “Sponges”
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 12, 2025, 07:54Aurelio Maggio Thanks Contributors to Webinar on Advanced Treatments in Rare Blood Disorders
-
Sep 12, 2025, 07:20Women for Their Health: Paige Bingham on Boston Scientific's Initiative ''Close the Gap'' Act During AFib Awareness Month
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births
-
Sep 11, 2025, 15:11Join the Global Effort: World Thrombosis Day Campaign for Healthcare and Community Organizations